Clinical trial
Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With…
NCT00470067 · Roswell Park Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00470067 |
|---|---|
| Title | Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer |
| Official title | A Multi-center Phase II Study of Doxil®/Carboplatin in Patients With Advanced or Recurrent Endometrial Carcinoma |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 9 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | May 7, 2007 |
| Last update posted | Aug 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: